What Could Be Propelling GlaxoSmithKline plc (ADR) to Decrease?

 What Could Be Propelling GlaxoSmithKline plc (ADR) to Decrease?

In today’s session GlaxoSmithKline plc (ADR) (GSK) recorded an unusually high (711) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the December, 2016 put, expecting serious GSK decrease. With 711 contracts traded and 2384 open interest for the Dec, 16 contract, it seems this is a quite bearish bet. The option with symbol: GSK161216P00037000 closed last at: $0.45 or 12.5% up. About 2.08 million shares traded hands. GlaxoSmithKline plc (ADR) (NYSE:GSK) has declined 8.33% since April 13, 2016 and is downtrending. It has underperformed by 12.25% the S&P500.

GlaxoSmithKline plc (ADR) (NYSE:GSK) Ratings Coverage

Out of 11 analysts covering GlaxoSmithKline (NYSE:GSK), 6 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 55% are positive. GlaxoSmithKline has been the topic of 16 analyst reports since September 8, 2015 according to StockzIntelligence Inc. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) has “Neutral” rating given on Tuesday, September 15 by BNP Paribas. Bank of America upgraded GlaxoSmithKline plc (ADR) (NYSE:GSK) on Tuesday, September 8 to “Neutral” rating. The rating was initiated by Piperjaffray on Friday, September 23 with “Overweight”. BNP Paribas downgraded the shares of GSK in a report on Wednesday, September 14 to “Underperform” rating. The company was upgraded on Thursday, July 14 by Jefferies. The rating was maintained by Argus Research on Monday, December 7 with “Buy”. The rating was upgraded by Bank of America to “Buy” on Wednesday, December 9. The firm earned “Buy” rating on Thursday, October 20 by Investec. The company was initiated on Friday, February 26 by Cantor Fitzgerald. The rating was upgraded by Bryan Garnier & Cie to “Buy” on Wednesday, January 27.

According to Zacks Investment Research, “GlaxoSmithKline is one of the world’s leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.”

GlaxoSmithKline plc is a healthcare company. The company has a market cap of $92.41 billion. The Firm is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. It has a 258.42 P/E ratio. The Company’s divisions include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

GSK Company Profile

GlaxoSmithKline plc (GSK), incorporated on December 6, 1999, is a healthcare company. The Firm is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in various therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV). The Company’s divisions include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Another recent and important GlaxoSmithKline plc (ADR) (NYSE:GSK) news was published by Businessfinancenews.com which published an article titled: “GlaxoSmithKline plc (ADR) Earning Release; Here’s What to Expect” on July 26, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags:

Related posts

Leave a Comment